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Abstract Insulin degludec (IDeg) is a new-generation
basal insulin with an ultra-long duration of action. To date, a
large number of studies have been conducted to investigate
the pharmacokinetic and pharmacodynamic properties of
IDeg. Standardised methods for collection and analysis of
blood samples (for pharmacokinetic endpoints) and eugly-
caemic clamp procedures (for pharmacodynamic endpoints)
were applied across studies to enable cross-study evaluation
of important pharmacokinetic and pharmacodynamic
parameters. Data show that IDeg has a half-life of [25 h
[compared with *12 h for insulin glargine (IGlar)] and
reaches steady state within 3 days of administration in all
patient populations investigated. The pharmacokinetic profile
of IDeg demonstrates an even distribution of exposure across
one dosing interval. The pharmacodynamic profile of IDeg is
flat and stable, demonstrated by an even distribution of
glucose-lowering effect across all four 6-h intervals in a 24-h
period (one dosing day). These properties were consistently
demonstrated across different type 1 and type 2 diabetes
mellitus patient populations, including those from different
ethnic origins (both males and females with type 2 diabetes),
the elderly, and patients with hepatic or renal impairment.
IDeg has an ultra-long duration of action exceeding 42 h and
demonstrates four times lower day-to-day within-subject
variability in glucose-lowering effect than IGlar. This review
discusses the pharmacokinetic and pharmacodynamic data
accumulated thus far, and the relevance of these results from
a clinical perspective.
1 Introduction
Patients with diabetes mellitus often require insulin sup-
plementation in order to maintain optimum blood glucose
levels and to prevent the diabetic complications that may
otherwise arise. Basal insulin analogues have therefore
been designed to mimic the action of endogenous insulin.
However, currently available basal insulins, including
insulin glargine (IGlar) and insulin detemir (IDet), have a
number of limitations that deviate from the ideal phar-
macokinetic and pharmacodynamic properties of a basal
insulin analogue. These limitations include a compara-
tively short half-life and a duration of action less than
24 h that does not consistently allow adequate glycaemic
control over a full 24-h period with once-daily dosing [1–
3]. As a result, these basal insulins are associated with a
glucose-lowering profile characterised by a period of low
activity gradually rising to a peak/plateau followed by a
decline (Fig. 1a). Subsequently, the pharmacokinetic and
pharmacodynamic limitations can necessitate more fre-
quent dosing of basal insulin in clinical practice to
maintain adequate blood glucose control [4–6] and man-
date that both IGlar and IDet are administered at the same
time every day [7, 8]. However, this can be perceived as
restrictive to patient lifestyle and can create a barrier
towards the use of basal insulin therapy [9, 10]. The lack
of a flat and stable glucose-lowering effect across one
dosing interval can make titration to an optimal dose
difficult in an individual subject, and can increase the risk
of hypoglycaemia [11, 12]. Unlike endogenous insulin
that is secreted from the pancreas in a glucose-dependent
manner, the dose of currently available basal insulins
needs to be titrated manually to maintain appropriate
levels in the body and avoid hypo- or hyperglycaemia
[13]. Therefore, minimising within-patient variability
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across a dosing interval (24 h) and from day to day is
imperative with any insulin therapy.
Current basal insulins are also unable to mimic the
physiological distribution of endogenous insulin. In theory,
a basal insulin analogue with a long half-life and duration
of action longer than 24 h should help to overcome this
unmet need in the treatment of diabetes. A longer duration
of action would lead to reduced peak to trough variations in
insulin concentration at steady state (SS) (Fig. 1b); SS is
when overall absorption and elimination are in dynamic
equilibrium with no further increase in the serum concen-
tration, and thus the amount of insulin available in circu-
lation between two doses would be more constant and
predictable [1, 14].
Insulin degludec (IDeg) is a new-generation basal
insulin with an ultra-long duration of action developed for
once-daily administration [15, 16], which has been
designed to address the unmet needs in terms of basal
insulin therapy outlined above. IDeg has distinct pharma-
cokinetic and pharmacodynamic characteristics that have
been thoroughly investigated and established across several
studies. Furthermore, the clinical benefits arising from
these properties have since been verified in a large clinical
trial programme (BEGIN) comprising over 11,000
patients in more than 40 countries. The purpose of this
review is to present and discuss the results from clinical
pharmacology studies conducted to date, and the clinical
relevance of the observed pharmacokinetic and pharma-
codynamic properties of IDeg.
2 Mechanism of Protraction of Insulin Degludec (IDeg)
The protein sequence of IDeg was based on human insulin,
modified by acylating DesB30 at the e-amino group of
LysB29 with hexadecandioic acid via a c-L-glutamic acid
linker [16]. To date, IDeg is the only insulin analogue to
self-associate into multi-hexamers upon subcutaneous (SC)
injection, resulting in a soluble depot from which IDeg is
slowly and continuously absorbed into the circulation
[15, 16].
In the pharmaceutical formulation, i.e. in the pre-
sence of phenol and zinc, the IDeg hexamers adopt a
conformation where only one of the ends is available to
interact with the side chain of another IDeg hexamer
and thus forms stable di-hexamers. Upon diffusion of
phenol following injection, the IDeg di-hexamers open
at both ends and lead to the formation of multi-hexa-
mers [16]. This mechanism is corroborated in an in vivo
study in pigs, which has demonstrated that IDeg forms
structures resembling the multi-hexamer formation of
IDeg upon SC injection [17], and supporting in vitro
observations [16] with electron microscopy [18]
(Fig. 2). With the gradual diffusion of zinc from the
ends of the multi-hexamers, terminal IDeg monomers
slowly and steadily dissociate, resulting in a slow and
gradual delivery of IDeg from the SC injection site into
the circulation [16]. In contrast, following SC injection,
IGlar forms microprecipitates that must re-dissolve prior
to absorption, which renders its absorption inherently
variable [19].
3 Main Data Collection Procedures
In studies investigating the pharmacokinetic and phar-
macodynamic properties of IDeg, the trial designs and
methodologies were specifically standardised, with only
minor variations made, where necessary, to enable
clinically relevant comparisons across different studies
and subject populations. The studies were conducted at
only a limited number of study centres to minimise
variability and maintain consistency in data collection
and analysis. A large proportion of the trial data were
collected using blood sampling (for pharmacokinetic
endpoints) and euglycaemic clamp procedures (for
pharmacodynamic endpoints). Only minor differences in
euglycaemic clamp methodology existed in studies with
subjects with type 1 (T1DM) or type 2 diabetes (T2DM),
due to factors such as the potential for endogenous
insulin secretion.
Consistency between studies was also maintained in
terms of the inclusion and exclusion criteria used for sub-
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Fig. 1 Conceptual model demonstrating action profiles with once-
daily dosing of a basal insulin with duration of action a B24 h and
b substantially longer than 24 h [14]
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minimise bias and confounding factors. For example, to
ensure the washout of all other insulins prior to adminis-
tering the first dose of the trial drug, the subjects were not
allowed to use IDet or IGlar for the preceding 48 h, and
intermediate-acting insulins such as neutral protamine
Hagedorn (NPH) or any pre-mixed insulin products during
the preceding 22 h [20–22]. In addition, a washout period
of 7–21 days was typically used when investigating the
effect of IDeg or other basal insulins in the same subject
[23–25]. Overarching exclusion criteria across all trials
also included smoking [24, 26] and subjects with a history
of recurrent severe hypoglycaemia or hypoglycaemic
unawareness [21, 22, 24, 25], again to minimise potential
variables that might have a confounding influence on data
interpretation.
3.1 Pharmacological Considerations
Basal insulins such as IDeg have a flatter profile owing to
reduced fluctuations in their glucose-lowering profile.
This property is directly related to their prolonged dura-
tion of action [1], as discussed in Sect. 1. Due to the
ultra-long duration of action of IDeg, most of the studies
were carried out at SS conditions, as the pharmacody-
namic profile after repeated dose administrations is not
identical to that after single-dose (SD) administration
[21]. Exceptions to this approach were in the special
population studies, including subjects with hepatic [27] or
renal impairment [28], and in a study including children
and adolescents in the study population [29] where mul-
tiple dosing of IDeg could not be conducted. In addition,
a SD was used in a glucose clamp study investigating
administration of IDeg at different injection sites in
healthy subjects [26]. In these studies, SS conditions were
modelled by simulating mean concentration–time and
glucose infusion rate (GIR) profiles based on the indi-
vidual SD profiles.
3.2 Pharmacokinetic Sampling
In all subjects in these studies, blood samples were col-
lected pre- and post-dose of IDeg at predefined timepoints
and intervals for pharmacokinetic analysis (as discussed in
each individual trial). Serum, urine and dialysate (where
relevant) concentrations of IDeg were measured using a
specific sandwich enzyme-linked immunosorbent assay
[21, 22, 27, 28].
3.3 Euglycaemic Clamp Methodology
Following administration of the last IDeg dose at the end of
each treatment period, subjects underwent a euglycaemic
clamp (of varying duration depending on the trial) per-
formed by means of a Biostator (MTB Medizintechnik,
Amstetten, Germany) [21, 22] or using a manual clamp, as
described previously [20].
4 Pharmacokinetic Characteristics of IDeg
4.1 Time to Steady State and the Half-Life of IDeg
The time from first dose of IDeg until serum trough
concentrations exceeded 90 % of the final plateau level,
generally regarded as the threshold for ‘clinical’ SS [30],
was used to define SS across all of the studies [14]. This
parameter is clinically relevant because one of the
potential concerns with a basal insulin with an ultra-long
Fig. 2 Mechanism of protraction of insulin degludec (IDeg) and
visualisation of IDeg using electron microscopy. a Schematic repre-
sentation of the formation of IDeg multi-hexamers in the subcutane-
ous depot from di-hexamers in the pharmaceutical formulation
[adapted from Jonassen et al. [16] (Fig. 5, p. 2,112), with kind
permission from Springer Science ? Business Media). b A transmis-
sion electron microscope image showing the effect of phenol on IDeg
multi-hexamer linkage—the figure depicts elongated IDeg structures
in the absence of phenol; the scale bar represents 200 nm (adapted
and reprinted with permission from Steensgaard et al. [18]; Copyright
2014 American Chemical Society)
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duration of action (IDeg) is the risk of insulin ‘stacking’;
that is, excessive accumulation of insulin, and consequent
hypoglycaemia [1]. Data show that in subjects with
T1DM the IDeg trough concentrations increased over the
first few days of treatment, before reaching a plateau;
thereafter, the IDeg concentration was unchanged from
day to day [14]. Clinical SS serum concentrations of IDeg
are reached within 3 days of once-daily IDeg dosing [14].
Similar results were also reported in elderly subjects
(C65 years) with T1DM [24] and in adult subjects with
T2DM [21]. The time to reach clinical SS was also
similar in subjects from different racial or ethnic back-
grounds, including Japanese subjects with T1DM [31] and
African American, Caucasian and Hispanic/Latino sub-
jects with T2DM [25]. The observed time to SS for IDeg
is in line with the findings that in drugs that follow first-
order kinetics (i.e. a constant fraction of the drug in the
body is eliminated for each unit of time, which applies for
IDeg and the majority of other drugs), drug concentration
reaches to within 98 % of the SS concentration at
approximately three times the drug half-life [32]. In
addition, a recent report further indicates that when rec-
ommended dosing guidelines and titration algorithms are
followed, insulin stacking with IDeg should not occur [1].
The half-life of IDeg in subjects with T1DM and T2DM
is found to be longer than 25 h across different patient
populations, as illustrated in Table 1a [21, 23, 25, 33],
which is twice that of IGlar (12 h) [23] (Table 1b). The
ultra-long half-life of IDeg leads to a flat pharmacokinetic
profile at SS conditions, resulting in low fluctuations in
glucose-lowering activity across one dosing interval [1], as
discussed below. The ultra-long half-life of IDeg also
results in longer availability of IDeg such that its levels are
measurable [120 h after dosing (which was the end of
observation) [20, 21, 34].
4.2 Pharmacokinetic Profiles
The pharmacokinetic properties of IDeg at clinical SS
have been investigated in several studies, including
subjects with T1DM [20, 23, 29, 34] or T2DM [21, 25].
Concentration–time curves obtained during one dosing
interval at SS conditions showed that the IDeg con-
centrations were consistent and evenly distributed over
a typical treatment interval of 24 h (s) (Fig. 3) [20, 34].
Furthermore, the total exposure of IDeg was found to
increase linearly in proportion with increasing dose
[23].
5 Pharmacodynamic Characteristics of IDeg
5.1 Pharmacodynamic Profiles
The ‘gold standard’ to determine the pharmacodynamic
properties of insulins is to measure the GIR during a
euglycaemic clamp (described above) [2]. Thus, the GIR
can be used as an indicator for the glucose-lowering
effect of the insulin investigated. The glucose-lowering
effect of IDeg has been shown to be flat and stable for a
Table 1 (A) Mean half-life of insulin degludec in subjects with type
1 or type 2 diabetes mellitus, including subjects with various racial
and ethnic backgrounds and (B) a comparison of the half-life of
insulin degludec versus insulin glargine is shown in subjects with
type 1 diabetes at all doses tested [23]
(A)
Type of diabetes Study population Half-life of IDeg (h)
T1DM Adults (18–65 years) [23] 25.4
Older adults (C65 years) [33] 25.4
T2DM Adults (18–70 years) [21] 25.1
Adults (18–70 years), Caucasian participants [25] 27.1
Adults (18–70 years), African American participants [25] 28.5
Adults (18–70 years), Hispanic/Latino participants [25] 22.8
(B)
Type of diabetes Dose (U/kg) Half-life of IDeg (h) Half-life of IGlar (h)
T1DM 0.4 25.9 11.5
0.6 27.0 12.9
0.8 23.6 11.9
Data are harmonic means
IDeg insulin degludec, IGlar insulin glargine, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus
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typical dosing interval of 24 h (or even longer) in
subjects with T1DM (Fig. 4a) [20, 23] or T2DM
(Fig. 4b) [21] across a range of clinically relevant dose
levels (0.4, 0.6 or 0.8 U/kg) [21, 23, 25]. The pharma-
codynamic properties of IDeg are preserved in subjects
with T2DM with different race/ethnic backgrounds, as
shown in Fig. 4c [25]. An even distribution of the glu-
cose-lowering effect of IDeg was also reported in Jap-
anese subjects with T1DM [31].
The flat shape of the pharmacodynamic profile of IDeg
is supported by parameters such as distribution of the
glucose-lowering effect and relative fluctuation. In fact,
both exposure and glucose-lowering effect of IDeg [in
terms of area under the curve (AUC)] have been shown
to be more evenly distributed than other basal insulins
across one dosing day in subjects with T1DM or T2DM
[21, 23]. The evenly distributed glucose-lowering effect
of IDeg was confirmed by the AUC for GIR (AUCGIR)
(A)












































































Fig. 3 Concentration–time profiles of insulin degludec 100 U/mL
(IDeg U100) dosed at 0.4 U/kg in subjects with a type 1 diabetes
mellitus [34] or b type 2 diabetes (data taken from Heise et al. [21]).
Also shown are the concentration–time profiles for c IDeg U100 and
IDeg 200 U/mL (IDeg U200) dosed at 0.4 U/kg in subjects with type
1 diabetes [reproduced from Korsatko et al. [20], Fig. 2a, p. 518],
with kind permission from Springer Science ? Business Media)




















































































Fig. 4 Glucose infusion rate profiles with insulin degludec (IDeg) for
subjects with a type 1 diabetes mellitus [23], b type 2 diabetes
(reproduced from Heise et al. [21], with permission from John Wiley
and Sons, Inc.) and c different race or ethnic backgrounds with type 2
diabetes (reprinted from Hompesch et al. [25], with permission from
Elsevier)
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across one 24-h dosing interval. IDeg demonstrated a
similar glucose-lowering effect over each of the four 6-h
intervals—it contributed approximately 25 % of the
AUCGIR,s,SS (the total glucose-lowering effect of IDeg
during s at SS)—whereas the majority of the effect of
IGlar occurred during the first 12–18 h after dosing
(Table 2). The relative fluctuation in GIR (where ‘relative
fluctuation’ represents the fluctuation in glucose-lowering
effect) was lower for IDeg than for IGlar [23]. These data
further support a flatter and more consistent 24-h phar-
macodynamic profile for IDeg than for IGlar [23]. Sim-
ilarly, in Japanese subjects with T1DM, the glucose-
lowering effect of IDeg was close to evenly distributed
(*50 %) across the first and second 12 h of the 24-h
dosing interval [31].
AUCGIR,s,SS has been demonstrated to increase in pro-
portion and linearly with increasing dose in subjects with
T1DM and T2DM, respectively [21, 23].
5.2 Duration of Action of IDeg
The duration of action of IDeg, defined as the time
from administration until blood glucose was consis-
tently above 150 mg/dL (or 8.3 mmol/L) [35], has been
shown to extend beyond 42 h (longest duration of
glucose clamp) in all investigated subjects with T1DM
receiving once-daily dosing of IDeg 0.4, 0.6 (Fig. 5a)
or 0.8 U/kg, with the exception of three subjects who
received IDeg 0.4 U/kg where the duration of action
ranged from 33 to 39 h [15, 34]. A duration of action
beyond 26 h has also been demonstrated for IDeg in
subjects with T2DM who underwent a euglycaemic
clamp for 26 h and received once-daily dosing of IDeg
0.4, 0.6 or 0.8 U/kg (Fig. 5b) [21]. Similar results have
also been reported in Japanese subjects with T1DM
[34] and subjects with T2DM from different racial and
ethnic backgrounds [25].
5.3 Variability in Glucose-Lowering Effect
Day-to-day within-subject variability with IDeg at SS in
glucose-lowering effect was investigated in a randomised,
single-centre, parallel-group, double-blind trial in subjects
with T1DM who were treated with 0.4 U/kg of IDeg or











IDeg 0.4 23 28 26 23
IGlar 0.4 31 29 23 17
IDeg 0.6 23 28 27 22
IGlar 0.6 29 30 24 17
IDeg 0.8 22 27 27 24
IGlar 0.8 28 30 25 17
Data are arithmetic means based on 21–22 patients per dose level for IDeg and 22 patients per dose level for IGlar
s typical dosing interval of 24 h at steady state, AUCGIR area under the glucose-infusion rate profile, IDeg insulin degludec, IGlar insulin
glargine, SS steady state












































Fig. 5 Duration of action of insulin degludec (IDeg) as indicated by
the duration of blood glucose control during glucose clamp exper-
iments in subjects with a type 1 diabetes mellitus (0.6 U/kg) [15] or
b type 2 diabetes (reproduced from Heise et al. [21], with permission
from John Wiley and Sons, Inc.)
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IGlar, administered once daily [22]. The subjects under-
went a 24-h euglycaemic glucose clamp on the sixth, ninth
and twelfth day of treatment, i.e. after SS had been
achieved. In this study, within-subject variability was
estimated using a linear mixed model on log-transformed
pharmacodynamic endpoints derived from the GIR profiles
during the clamps [22].
The study demonstrated four-times lower within-sub-
ject variability (AUCGIR,s,SS [glucose-lowering effect of
IDeg at SS during one dosing interval (0–24 h)]) with
IDeg [coefficient of variation (CV) 20 %] than IGlar (CV
82 %) (p \ 0.0001). Significantly lower within-subject
variability in the level of maximum effect (GIRmax,SS) for
IDeg (CV 18 %) versus IGlar (CV 60 %) (p \ 0.0001)
was also reported [22]. As shown in Fig. 6, subject-spe-
cific CVs (%) for AUCGIR,s,SS were consistently lower for
IDeg than for IGlar when the individual CVs (%) were
compared in ranked order. The estimated difference
between IDeg and IGlar in within-subject variation was
driven by fluctuation in the majority of the subjects
receiving IGlar rather than any extreme variability dem-
onstrated by outliers, particularly for IGlar (Fig. 6) [22].
Furthermore, this was consistent throughout the 24-h
period. As illustrated in Fig. 7, the within-patient vari-
ability for 2-h intervals of AUCGIR was consistently low
with IDeg and significantly lower with IDeg than with
IGlar over the entire 24-h dosing interval at SS [22]. In
comparison, the variability of IGlar was significantly
higher and increased substantially 6–8 h after dosing,
reaching a maximum at 14–16 h after dosing [22]. These
observations are in agreement with the general principle
that a basal insulin with an ultra-long duration of action
should have lower variability than a basal insulin with a
shorter duration of action where the effects of several
injections overlap and minimise changes in absorption in
either direction, as discussed in Sect. 1. Moreover, the
distinct mechanism of protraction of IDeg offers specific
advantages in reducing within-subject variability, such as
it remaining in solution after SC injection, unlike IGlar
which forms microprecipitates after injection that must re-
dissolve before absorption [22]. This latter property is
most likely one of the causes for the higher variability
observed for IGlar, as discussed in Sect. 2.
On the basis of the estimated within-subject CV of
maximum glucose-lowering effect, the risk of experiencing
more than double the usual maximum effect on any given
day (i.e. potential hypoglycaemia) has been projected to be
\0.1 % for IDeg and 11 % for IGlar [22]. Similarly, the
risk of experiencing less than half the average effect on any
given day (i.e. potential hyperglycaemia) was projected as
\0.1 % for IDeg and 17 % for IGlar [22].
6 Pharmacokinetic and Pharmacodynamic
Characteristics of IDeg across Different
Formulations, Special Patient Populations
and Various Injection Sites
6.1 Comparison of Two Different Formulations
of IDeg: 100 and 200 U/mL
IDeg is available in two strengths—100 U/mL (U100) and
200 U/mL (U200)—with the latter designed to allow the
administration of up to 160 units of IDeg in a single
injection to help reduce injection volumes for patients with
large insulin requirements. During development, the U200

























Fig. 6 Subject-specific day-to-day variability in the area under the
glucose infusion rate curve for insulin degludec (IDeg) or insulin
glargine (IGlar) dosed at 0.4 U/kg during one dosing interval
(0–24 h) at steady state (reproduced from Heise et al. [22], with



































































Fig. 7 Day-to-day variability in glucose-lowering effect of insulin
degludec (IDeg) and insulin glargine (IGlar) dosed at 0.4 U/kg over
24 h at steady state (reproduced from Heise et al. [22], with
permission from John Wiley and Sons, Inc.). AUCGIR area under
the glucose infusion rate profile, CV coefficient of variation
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formulation was optimised with a slight adjustment of the
excipients in order to obtain the same pharmacological
properties and effect as U100. To demonstrate this further,
a comparison of the pharmacokinetic and pharmacody-
namic properties between the two IDeg formulations (U100
and U200) was made in a double-blind, crossover, ran-
domised study in subjects with T1DM under SS conditions
[20]. The study demonstrated that the U200 concentration–
time profile is similar to the U100 profile (Fig. 3c). A post
hoc analysis of this study also demonstrated that the two
IDeg formulations fulfil the criteria for bioequivalence set
by the US Food and Drug Administration (FDA) and
European Medicines Agency (EMA) [36, 37], as the 90 %
confidence intervals (CIs) of the U200/U100 ratios for total
exposure (AUC) to IDeg and maximum IDeg concentration
at SS were within the interval 0.80–1.25, as were the 95 %
CIs for the primary endpoint of AUCGIR,s,SS [ratio of
U200:U100 0.94 (95 % CI 0.86–1.03)]. The maximum
GIR at SS was also similar for IDeg U100 and IDeg U200
[2.4 and 2.1 mg/(kgmin), respectively] [20].
Both exposure and glucose-lowering effect of IDeg were
evenly distributed over one dosing interval with both for-
mulations, such that the exposure of IDeg at SS for the first
12-h interval versus the entire 24-h interval (AUCIDeg,0–12h,SS/
AUCIDeg,s,SS) was 55 % with IDeg U100 and 53 % with
IDeg U200, and AUCGIR,0–12h,SS/AUCGIR,s,SS was 48 %
with IDeg U100 and 46 % with IDeg U200 [20]. Similar
results with IDeg U200 were also observed in subjects with
T2DM, such that the AUCGIR was *50 % for each of the
two 12-h intervals [38].
6.2 Children and Adolescents
Previous investigations with another basal analogue have
shown that the pharmacological exposure can be higher in
children and adolescents than in adults [39]. Therefore, a
single-centre, randomised, SD, double-blind, two-period
crossover trial with IDeg was conducted in children
(6–11 years), adolescents (12–17 years) and adults
(18–65 years) with T1DM [29]. In general, the study found
that the pharmacokinetic properties of IDeg observed in
adults are preserved in children and adolescents with
T1DM. A population pharmacokinetic model was used to
simulate the mean SS pharmacokinetic profile of IDeg
from this SD study. The simulated mean SS pharmacoki-
netic profiles supported a flat and stable IDeg exposure
across a 24-h dosing interval in all of the sub-populations
[29]. In line with previous investigations with other basal
insulins, the total exposure (AUCIDeg,0–?,SD) and maxi-
mum concentration (Cmax) of IDeg after a SD (Cmax,-
IDeg,SD) were higher in children and adolescents than in
adults [estimated ratio for AUCIDeg,0–?,SD children/adults
1.48 (95 % CI 0.98–2.24) and adolescents/adults 1.33
(95 % CI 1.08–1.64); estimated ratio for Cmax,IDeg,SD
children/adults 1.20 (95 % CI 0.90–1.60) and adolescents/
adults 1.23 (95 % CI 1.00–1.51)]; however, the difference
was only statistically significant for AUCIDeg,0–?,SD in
adolescents versus adults [29]. A larger joint analysis of the
SD data from this trial and SS population pharmacokinetic
data from a larger (n = 169) clinical study in children and
adolescents [40] found that SS IDeg exposure was inde-
pendent of age, with similar IDeg concentration–time
profiles observed for smaller children (1–5 years), children
aged 6–11 years, adolescents (12–17 years) and adults
(18–65 years) with T1DM (Fig. 8) (Novo Nordisk).
6.3 Renal or Hepatic Impairment
It is widely accepted that the liver and kidneys play sig-
nificant roles in insulin clearance [41]. However, insulin
clearance is specifically mediated by the trafficking and
internalisation of the insulin receptor, which might be even
more predominant in albumin-bound insulins that cannot
be filtered via the renal route as easily as unbound ‘free’
insulins. As a result, renal and hepatic impairment may not
have a large effect on the pharmacological properties of
basal insulin analogues. In fact, evidence to date indicates
that while renal impairment may affect the pharmacoki-
netic parameters of some glucose-lowering therapies, such
as oral antidiabetic drugs and some dipeptidyl peptidase-4
inhibitors [42, 43], studies have shown that the pharma-
cokinetic properties of insulin analogues do not appear to
be affected by renal impairment [41]. This finding is
Time since injection (hours)
0



















Adolescents (12–17 years, Median BW=58.0 kg)
Adults (18–65 years, Median BW=78.5 kg)
Children (6–11 years, Median BW=34.2 kg)
Small Children (1–5 years, Median BW=17.7 kg)
Fig. 8 Simulated insulin degludec (IDeg) concentration–time profiles
at steady state in smaller children (1–5 years), children (6–11 years),
adolescents (12–17 years) and adults (18–65 years) over a 24-h
dosing interval. The simulation was made using the final model from
a joint analysis of the pharmacokinetic data from a single-dose trial
with IDeg in children, adolescents and adults with type 1 diabetes
mellitus (N = 36) [29] and steady-state population pharmacokinetic
data obtained over 26 weeks in a clinical trial with IDeg in children
and adolescents with type 1 diabetes (N = 169) [40]. The profiles
shown are (median) for a typical subject in each age group [with body
weight (BW) equal to the median BW in that age group]
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further corroborated in a SD, open-label, parallel-group
trial that demonstrated the pharmacokinetic characteristics
of IDeg are preserved in adult subjects with different
degrees of renal impairment [28]. Total exposure and Cmax
of IDeg, as well as the apparent total clearance from
plasma after SC administration (CL/F) of IDeg were
comparable in subjects with normal and varying degrees of
impaired renal function (Table 3).
Haemodialysis did not affect the pharmacokinetic pro-
file of IDeg in subjects with end-stage renal disease
(ESRD) undergoing haemodialysis. Both total exposure
(AUCIDeg,0–?) and Cmax (Cmax,IDeg) of IDeg in ESRD
subjects were comparable with the results obtained in the
other subject groups with normal or varying degrees of
impaired renal function (Table 3). Moreover, haemodialy-
sis was also shown not to have a statistically significant
effect on CL/F of IDeg (mean ratio before/after dialysis
1.23, 95 % CI 0.92–1.66) [28]. Minimal clearance of IDeg
during haemodialysis was further supported by the evi-
dence that in this study, all concentrations of IDeg in the
dialysate were below the lower limit of quantification
(100 pmol/L) [28].
In addition, pharmacokinetic properties of IDeg have
been shown to be preserved in subjects with impaired
hepatic function compared with subjects without any
hepatic function impairment, as summarised in Table 3. A
test of monotonous trend between the grade of hepatic
impairment and total exposure (AUCIDeg,0–120h) was found
not to be statistically significant (p = 0.63) [27].
Simulated mean SS profiles demonstrated an even dis-
tribution of exposure to IDeg across a 24-h dosing interval,
regardless of renal or hepatic function status, indicating
that the pharmacokinetic properties observed in patients
with normal renal or hepatic function are preserved in
patients with impaired renal or hepatic function [27, 28].
Based on the presented results, dose titration with IDeg can
be performed similarly in patients with impaired renal or
hepatic function compared with patients with normal organ
functions.
6.4 Variation in Injection Site
Previous studies with other analogues have shown that
pharmacological effects of basal insulin analogues can vary
with different regions following SC administration [44–
47]. Since IDeg can be injected in different parts of the
body, it is important to investigate the potential impact of
injection region on its pharmacological effects. A ran-
domised, open-label, five-period, single-centre, SD cross-
over trial found that there were no major differences in
IDeg exposure following a single SC injection of IDeg in
the deltoid, abdomen or thigh [26]. AUCIDeg,0–120h and
Cmax,IDeg were 6–7 and 23–27 % higher, respectively,
following a single SC dose in the deltoid or abdomen,
compared with the thigh, as also observed with other
insulin preparations [46]. No difference in exposure was
observed between administration in the deltoid or abdo-
men. Similarly, no pronounced differences were observed
in the glucose-lowering effect of IDeg [AUCGIR,0–24h,SD
and maximum GIR after a SD (GIRmax,SD)] when injected
in the thigh, abdomen or deltoid (AUCGIR,0–24h,SD 2,572,
2,833 and 2,960 mg/kg, respectively). As the differences in
glucose-lowering effect of IDeg following a SD were only
minor between the three injection regions, it is possible that
these would be negligible at SS conditions where IDeg
demonstrates flat and consistent pharmacokinetic and
pharmacodynamic profiles [26].
This is further supported by the evidence that, at simu-
lated SS conditions, AUCIDeg,s,SS and Cmax,IDeg at SS
(Cmax,IDeg,SS) were estimated to be only *8 and 10 %
higher, respectively, following injection in the deltoid or
abdomen, compared with the thigh. In addition, the
Table 3 Relationship between degree of renal or hepatic impairment and insulin degludec pharmacokinetic parameters [adapted from Kupcˇova´
et al. [27] (Table 2, p. 131) and Kiss et al. [28] (Table 4, p. 180), with kind permission from Springer Science ? Business Media)
Comparison of grades of renal/hepatic impairment Renal impairment study [28] Hepatic impairment study [27]
AUCIDeg,0–? Cmax,IDeg AUCIDeg,0–120h Cmax,IDeg
Mild vs. normal 1.11 (0.80–1.54) 1.14 (0.81–1.61) 0.95 (0.77–1.16) 0.90 (0.67–1.20)
Moderate vs. normal 1.11 (0.80–1.53) 1.06 (0.76–1.49) 1.00 (0.82–1.22) 0.77 (0.58–1.03)
Severe vs. normal 1.19 (0.86–1.65) 1.23 (0.87–1.73) 0.92 (0.74–1.14) 0.75 (0.55–1.02)
ESRD vs. normal 1.02 (0.74–1.40) 1.05 (0.75–1.46) N/A N/A
Data are expressed as ratio (90 % confidence interval)
Pair-wise comparisons are shown for subjects with impaired renal function and those with normal renal function after a single dose of IDeg. Data
in ESRD groups are based on pharmacokinetic profiles (excluding a haemodialysis session) [28]. For the data from the hepatic impairment study,
the endpoints were log-transformed and analysed using an analysis of variance model with hepatic function group, sex and age at baseline as
fixed effects [27]
AUC area under the plasma concentration–time curve, Cmax maximum concentration, ESRD end-stage renal disease, IDeg insulin degludec, N/A
not applicable
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simulated mean SS pharmacodynamic profile supports a
flat and stable IDeg exposure and effect, regardless of
injection region, with comparable total glucose-lowering
effects between the thigh, abdomen and deltoid. Conse-
quently, the small differences in glucose-lowering effect
following a SD of IDeg in three injection regions are
expected to be of limited clinical relevance [26].
7 Clinical Relevance of the Pharmacokinetic
and Pharmacodynamic Characteristics of IDeg
As discussed, the improved properties of IDeg have dem-
onstrated benefits in pharmacokinetic and pharmacody-
namic studies. The more even distribution, flatter glucose-
lowering profile and reduced day-to-day within-patient
variability should allow clinically relevant improvements
such as tighter blood glucose control [improved control of
levels of glycated haemoglobin (HbA1c) and fasting plasma
glucose concentration] and avoidance of hypoglycaemia, in
particular nocturnal hypoglycaemia.
All of the phase III trials with IDeg were designed as
treat-to-target trials striving for an ambitious (fasting)
blood glucose level target of 4–5 mmol/L (70–90 mg/dL).
As a result of the treat-to-target design, a comparison can
be made in terms of differences in endpoints such as
hypoglycaemia (but not, for example, HbA1c), as illustrated
in Table 4 [48–54]. A pre-planned meta-analysis examin-
ing hypoglycaemia rates compared with IGlar across the
phase IIIa programme showed a 17 % reduction in epi-
sodes of overall confirmed hypoglycaemia [estimated rate
ratio (ERR) 0.83, 95 % CI 0.74–0.94] and 32 % reduction
in nocturnal confirmed hypoglycaemia (ERR 0.68, 95 % CI
0.57–0.82) during the entire treatment period in subjects
with T2DM [55]. In subjects with T1DM, no statistically
significant difference was observed in the rates of overall
confirmed hypoglycaemia (ERR 1.10, 95 % CI 0.96–1.26),
although the reduction in nocturnal confirmed hypogly-
caemia (ERR 0.83, 95 % CI 0.69–1.00) between IDeg and
IGlar nearly reached statistical significance. In the pooled
population combining subjects with T1DM and T2DM, the
relative rate of nocturnal confirmed hypoglycaemia was
found to be 26 % lower with IDeg than with IGlar [55].
Interestingly, a separate phase II study with a different
long-acting basal insulin (LY2605541) also reported higher
rates of overall hypoglycaemia (p = 0.037) with
LY2605541 than with IGlar, but lower rates of nocturnal
hypoglycaemia (p = 0.012) in subjects with T1DM [56].
The numerically higher rate of overall confirmed hypo-
glycaemia in subjects with T1DM receiving IDeg may be
attributed to the starting dose of basal insulin potentially
being higher than necessary to maintain glycaemic control,
where the patients on twice-daily basal insulin were
switched 1:1 to IDeg [48]. In contrast, patients switching
from twice-daily basal to IGlar reduced their dose by
20–30 % (according to label) when switching, and thus
minimised the risk of hypoglycaemia [48]. Therefore, a
dose reduction when switching to IDeg may help to lower
the risk of hypoglycaemia. This rationale is furthered
supported by the reduction in rates of hypoglycaemia, in
particular nocturnal hypoglycaemia episodes, being more
prominent with IDeg than with IGlar during the mainte-
nance phase—described as the period (from 16 weeks to
end of treatment) when stable glycaemic control and
insulin dose have been achieved [55]. In subjects with
T1DM, a 25 % reduction in the rates of nocturnal con-
firmed hypoglycaemia was observed with IDeg compared
to IGlar (ERR 0.75, 95 % CI 0.60–0.94) and a 38 %
reduction in subjects with T2DM (ERR 0.62, 95 % CI
0.49–0.78) during the maintenance phase [55]. Overall,
these results further demonstrate that the pharmacokinetic
and pharmacodynamic properties of IDeg can translate into
relevant clinical benefits.
The reduced variability in glucose-lowering effect,
associated with IDeg, should facilitate better titration
and management of overall glycaemic control. Owing to
its ultra-long duration of action ([42 h) and reduced
within-subject variability, IDeg offers the potential for a
more flexible dosing window. This is supported by two
treat-to-target, randomised studies where extreme dosing
intervals of 8–40 h were used in subjects with T1DM
and T2DM over a treatment duration of 26–52 weeks
[49, 53]. The studies found that, even with such extreme
dosing windows, glycaemic control and safety with
IDeg were not compromised in comparison to the sub-
jects receiving IDeg or IGlar once daily always at the
same time of day [49, 53]. The possibility for a more
flexible dosing window may help improve patient
adherence and thereby facilitate optimum glycaemic
control, as discussed in Sect. 1.
8 Potential Risk Factors and Limitations Associated
with an Ultra-Long-Acting Basal Insulin
The ultra-long duration of IDeg provides at least 24 h of
insulin coverage. As with any new product, it is imperative
to examine any potential risk factors that might arise from
the markedly different properties of IDeg compared with
currently available basal insulins. Similar to all insulin
analogues, the risk of hypoglycaemia is a major safety
concern, and is considered a key obstacle in regulating
blood glucose levels by both patients and physicians [10,
57]. Although the number of hypoglycaemic events is
important, the type and duration of a hypoglycaemic epi-
sode is also of relevance, especially when using a basal
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insulin with an ultra-long duration of action. In order to
assess this risk, a double-blind, randomised, crossover trial
was conducted in subjects with T1DM to investigate the
impact of IDeg on the counter-regulatory hormone
response to hypoglycaemia during the development of and
recovery from hypoglycaemia, compared with subjects
receiving IGlar [58].
The hypoglycaemic response with IDeg and IGlar was
determined with respect to hypoglycaemic symptom score
(HSS) at a nadir plasma glucose concentration of
2.5 mmol/L during induced hypoglycaemia where blood
glucose levels were controlled using a clamp methodology,
as discussed in detail in Koehler et al. [58]. While moderate
increases in counter-regulatory hormone responses were
observed with IDeg compared with IGlar around the glu-
cose nadir, in addition to a lower GIR with IDeg during
recovery than with IGlar, this did not have an obvious
effect on the HSS or cognitive function. During recovery
from hypoglycaemia, mean HSS returned to baseline at a
similar rate for IDeg and IGlar. The study therefore showed
that the longer duration of action of IDeg than of IGlar does
not affect the nature of, or time to recovery from, a hy-
poglycaemic episode [58].
Exercise-related hypoglycaemia is also a concern of
subjects with diabetes, due to the increased requirement for
glucose during exercise, as well as higher insulin sensi-
tivity that can lead to hypoglycaemia [59]. This concern is
further compounded since the dose of basal insulin (IDeg)
cannot be reduced in the short-term. In order to investigate
whether the pharmacokinetic and pharmacodynamic
properties of IDeg can in any way alter the susceptibility to
exercise-related hypoglycaemia compared with other basal
insulins, a randomised, open-label, two-period, multiple-
dose, crossover trial was initiated in 40 subjects with
T1DM [60]. This study reported that similar blood glucose
concentrations and a similar (low) incidence of hypogly-
caemic episodes were observed during and 24 h after
exercise in subjects receiving either IDeg or IGlar [60].
Furthermore, a meta-analysis of seven randomised, open-
label, treat-to-target clinical trials [61] reported that IDeg
administered once daily does not lead to an increased
susceptibility to exercise-related hypoglycaemia compared
with IGlar once-daily administration, as a similar propor-
tion of subjects experienced C1 episodes of confirmed
exercise-related hypoglycaemia.
Another clinical concern with IDeg includes the potential
for immunogenicity. However, the concentration of IDeg-
specific antibodies and antibodies cross-reacting with IDeg
and human insulin was found to be low in studies in patients
with T1DM [48, 49] or T2DM [50, 53], indicating that the
risk of immunogenicity with IDeg is minimal. Furthermore,
the studies showed that there was no apparent association
between the development of cross-reacting antibodies and
hypoglycaemia, HbA1c or insulin dose [48, 49, 53].
Due to the ultra-long duration of action of IDeg, there
may also be a need to understand better how patients adapt
to the use of bolus insulin in combination with IDeg in
clinical practice.
In addition, it should be noted that while IDeg is
approved for use in many countries, including countries in
Table 4 Summary of efficacy and hypoglycaemia data for insulin degludec versus insulin glargine in clinical trials in adult subjects with type 1
or type 2 diabetes mellitus
Study name Study population Efficacy Changes in the rate of
hypoglycaemia with IDeg vs.
IGlar (% reduction)
Reduction in HbA1c
with IDeg vs. IGlar,
ETD (%)
Reduction in FPG levels








BEGIN: T1 [48] T1DM -0.01; non-inferior -0.33 7 : 25 ;
BEGIN: Flex T1 [49]a T1DM 0.17; non-inferior -0.05 3 : 40 ;
BEGIN: Once Long [50] T2DM, insulin naive 0.09; non-inferior 20.43 18 ; 36 ;
BEGIN: LOW VOLUME [51] T2DM, insulin naive 0.04; non-inferior 20.42 14 ; 36 ;
BEGIN: BB [52] T2DM 0.08; non-inferior -0.29 18 ; 25 ;
BEGIN: FLEX [53]b T2DM, insulin naive
and insulin treated
0.04; non-inferior 20.42 3 : 23 ;
BEGIN: ONCE ASIA [54] T2DM, insulin naive 0.11; non-inferior -0.09 18 ; 38 ;
The values in bold indicate a significant difference between insulin degludec and insulin glargine (p \ 0.05)
ETD estimated treatment difference, FPG fasting plasma glucose, HbA1c glycated haemoglobin, IDeg insulin degludec, IGlar insulin glargine,
T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus
a IDeg ‘Forced-flex’ (IDeg administered in a fixed schedule with 8–40 h interval between doses) data compared with IGlar
b IDeg ‘Flex’ (IDeg administered in a pre-specified dosing schedule with 8–40 h interval between doses) data compared with IGlar
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the European Union, Russia, Switzerland, Iceland, Nor-
way, Montenegro, Japan, Hong Kong, South Korea, India,
Nepal, Bangladesh, Israel, United Arab Emirates, Mexico,
Honduras, Brazil, Lebanon, Macedonia, El Salvador, Chile,
Argentina, Aruba, South Africa and Costa Rica, it has not
yet been approved in the USA. The FDA raised concerns
about the cardiovascular safety of IDeg based on results
from one of several requested post hoc analyses, and the
pre-specified definition of major cardiovascular events used
in the analyses [62]. These same data have been presented
to other regulatory agencies such as the EMA and the
Pharmaceuticals and Medical Devices Agency, Japan
(PMDA), who have approved IDeg in full knowledge of
the FDA decision. In order to demonstrate the cardiovas-
cular safety of IDeg, Novo Nordisk has initiated a large
cardiovascular outcomes study that is ongoing (Clinical-
Trials.gov study identifier NCT01959529—the DegludEc
cardioVascular OuTcomEs trial (DEVOTE) trial) [63].
9 Conclusion
The pharmacokinetic and pharmacodynamic characteristics
of IDeg target and address many of the unmet needs in
diabetes management, which was the main basis for its
development, as summarised in Table 5. As a result,
compared with first-generation basal insulin analogues,
IDeg offers the possibility for a simple titration algorithm
and the potential for a more flexible dosing interval to
accommodate varying patient lifestyles. This could help
improve adherence and ultimately contribute towards
improved glycaemic control in patients with diabetes [64].
In addition, flexibility in the dosing interval may also
facilitate earlier acceptance and use of basal insulin ther-
apy. From a pharmacological perspective, IDeg as a new
and improved basal insulin offers substantial opportunity
for subjects with diabetes. However, there are still areas
where further improvement in the treatment of diabetes
would offer added benefit; for example, by the develop-
ment of a glucose-sensitive basal insulin, a basal insulin
with hepatoselectivity, or a basal insulin with an even
longer duration of action. In fact, longer-acting basal
insulin analogues with the potential for once-weekly dos-
ing are currently in development (e.g. product NNC0148-
0000-0287, alternatively known as insulin 287, under
development by Novo Nordisk and a recombinant human
basal insulin, AB101, under development by AntriaBio,
Inc.) and studies are already underway (ClinicalTrials.gov
study identifier NCT01730014) [65]. Such products could
potentially provide even more convenient and effective
treatment for diabetes in the future.
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